| 发明名称 |
Crystal forms |
| 摘要 |
The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-10. |
| 申请公布号 |
US9593078(B2) |
申请公布日期 |
2017.03.14 |
| 申请号 |
US201514707433 |
申请日期 |
2015.05.08 |
| 申请人 |
AbbVie Inc. |
发明人 |
Califano Jean-Christophe;Fickes Michael G.;Nordstroem Lars Fredrik |
| 分类号 |
C07D401/14;C07D207/16;C07D405/14;C07D413/14;A61K38/05;A61K31/4178;C07D401/10;C07D403/14;C07D417/14;C07D519/00 |
主分类号 |
C07D401/14 |
| 代理机构 |
|
代理人 |
Zhang Xu |
| 主权项 |
1. A process for making a pharmaceutical composition comprisingcomprising dissolving a crystalline form of Compound I in a solvent, wherein said crystalline form has characteristic peaks in PXRD pattern as described in one of Tables 1-10 when tested using a diffractometer that is operated with a copper anode tube at 40 kV and 30 mA and a germanium monochromator to provide monochromatic Cu-Kα radiation with a wavelength of 1.54178 Å. |
| 地址 |
North Chicago IL US |
